Invitrocue Limited has entered into a partnership with Pangaea Oncology SA to supply ACE-2 HiMice to Pharma Mar SA for their in-vivo study of vaccine candidate against Covid 19 virus. The in-vivo study will be conducted by Invivocue and coordinated by Pangaea while Pharma Mar will provide the vaccine candidate for the study. The contract is worth approximately 80,000, and Invivocue expects to receive about 55,000. All intellectual property rights arising out of the study will be owned by Pharma Mar SA. The IP rights to the platform will still be under Accelerate Technologies with Invivocue having the right to use it as mentioned above. The study is expected to be completed by first quarter of 2021. The agreement contains various other provisions considered standard for agreements of this nature.